Biology-first resolution
Focus on tissue and cell context rather than isolated biomarker readouts, so molecular findings are interpreted in relation to their biological origin.
About Us
Precision medicine through tissue-resolved molecular insight.
We envision a future in which disease is detected earlier, treated effectively, and monitored through a simple blood test by understanding its biological origin.
Focus
High-resolution liquid biopsy
Approach
AI-assisted multi-omics interpretation
Goal
Earlier detection and targeted care
Our Mission
To deliver comprehensive health insights from a standard blood draw.
We decode health and disease at the level of tissues and cells by combining multi-modal biology and AI to translate molecular signals from blood into interpretable clinical insight, enabling earlier detection and more personalized care.
Multi-layer signal interpretation
Combine advanced sequencing and AI to read genetic, epigenetic, and fragmentomic information as part of one coherent decision layer.
Clinical translation
Deliver patient-centric workflows for earlier detection, risk stratification, and targeted therapy in scalable liquid biopsy test settings.
Our Story
From patented multi-omics technology to first clinical applications.
Aitiologic builds on multi-omics technology originally invented at Siemens Healthineers and is now advancing that foundation toward first applications such as preeclampsia screening.
Why the name
Our name derives from the Greek word aitios, meaning cause. It reflects our focus on decoding the molecular origins of disease rather than observing biological signals in isolation.
Network & Development Partners
Supported by leading funding, innovation, and technology partners.
We are redefining precision medicine together with public innovation programs, startup support partners, and leading technology organizations.
